Page last updated: 2024-11-12
azidocillin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
azidocillin: antibiotic similir to ampicillin; minor descriptor (75-86); on line & INDEX MEDICUS search PENICILLIN G/AA (75-86); RN given refers to (2S-(2alpha,5alpha,6beta(S*))-isomer) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 15574941 |
CHEMBL ID | 2105907 |
CHEBI ID | 51758 |
MeSH ID | M0263147 |
Synonyms (42)
Synonym |
---|
17243-38-8 |
2,2-dimethyl-6beta-[(2r)-2-azido-2-phenylacetamido]penam-3alpha-carboxylic acid |
CHEBI:51758 , |
azidocilline |
azidocillinum |
(2s,5r,6r)-6-{[(2r)-2-azido-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
azidocillin |
azidocilina |
d-(-)-(alpha-azidobenzyl)penicillin |
DB08795 |
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid, 6-[[(2r)-azidophenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2s,5r,6r)- |
spc 297 d |
brl 2534 |
azidocillina |
spc-297-d |
CHEMBL2105907 |
brl-2534 |
6-(2-azido-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-4-azabicyclo(3.2.0)heptane-2-carboxylic acid |
r8xdp7l3sl , |
azidocillinum [inn-latin] |
azidocilina [inn-spanish] |
einecs 241-278-5 |
(2s,5r,6r)-6-((r)-2-azido-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure |
azidocilline [inn-french] |
unii-r8xdp7l3sl |
azidocillina [dcit] |
azidocillin [inn:ban] |
6-(2-azido-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid |
d-(-)-(.alpha.-azidobenzyl)penicillin |
azidocillin [who-dd] |
azidocillin [inn] |
(2s,5r,6r)-6-((r)-2-azido-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylic acid |
azidocillin [mi] |
(2s,5r,6r)-6-[(2r)-2-azido-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
(2s,5r,6r)-6-((r)-2-azido-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
DTXSID20938154 |
Q4832566 |
(2s,5r,6r)-6-[[(2r)-2-azido-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
brl 2351; brl 2534; d-(-)--azidobenzylpenicillin; dan 10510; spc 297d; spc 97d |
CS-0017507 |
HY-B2091 |
gtpl12291 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
"Intestinal absorption rate constants of amoxicillin, ampicillin, epicillin, cyclacillin and azidocillin, by means of a static in situ intestinal perfusion method has been estimated." | ( Intestinal absorption kinetics of a series of aminopenicillins and azidocillin. A comparative study in the rat. Margarit, F; Moreno-Dalmau, J; Obach, R; Peraire, C; Plá-Delfina, JM, 1991) | 0.74 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" dosage were 57-60% for the tablets and 64% for the suspension." | ( Pharmacokinetics of azidocillin in healthy adults. Bergan, T; Sørensen, G, 1980) | 0.58 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
penicillin | Any member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 10 (83.33) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (8.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 25.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.57) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 7 (41.18%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (5.88%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (52.94%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |